Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

An experimental drug for Parkinson’s disease that Roche has been developing for more than a decade just flunked another key ...